Pharmacological and clinical evaluation of a new anti-flu drug, baloxavir marboxil

doi:10.5246/jcps.2020.10.068

Abstract

Abstract:

Baloxavir marboxil is a polymerase acidic (PA) endonuclease inhibitor, which is approved by the U.S Food and Drug Administration (FDA) on October 25, 2018, for the treatment of uncomplicated influenza patients aged 12 years and older. In the present work, we reviewed the pharmacodynamics, pharmacokinetics, drug interactions, clinical trials and adverse reactions of baloxavir marboxil.

Key words: Baloxavir marboxil, Pharmacodynamics, Pharmacokinetics, Adverse reactions

CLC Number:

R961

Supporting:

Jingjing Cao, Jun Sun, Shujuan Zhao, Peizhi Ma. Pharmacological and clinical evaluation of a new anti-flu drug, baloxavir marboxil[J]. Journal of Chinese Pharmaceutical Sciences, 2020, 29(10): 729-733.

References

[1] FDA. Highlights of prescribing information. 2018, 10, 24. http://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210854s000lbll.pdf

[2] Takashita, E.; Morita, H.; Ogawa, R.; Nakamura, K.; Fujisaki, S.; Shirakura, M.; Kuwahara, T.; Kishida, N.; Watanabe, S.; Odagiri, T. Susceptibility of influenza viruses to the novel cap-dependent endonuclease inhibitor baloxavir marboxil. Front Microbiol. 2018, 9, 3026.

[3] Gonzalez-Motos, V.; Jurgens, C.; Ritter, B.; Kropp, K.A.; Durán,V.; Larsen,O. Varicella zoster virus glycoprotein C increases chemokine-mediated leukocyte migration. PLoS Pathog. 2017, 13, e1006346.

[4] Reich, S.; Guilligay, D.; Pflug, A.; Malet, H.; Berger, I.; Crépin, T.; Hart, D.; Lunardi, T.; Nanao, M.; Ruigrok, R.W.; Cusack, S. Structural insight into cap-snatching and RNA synthesis by influenza polymerase. Nature. 2014, 516, 361–366.

[5] Shi, F.Y.; Xie, Y.C.; Shi, L.F.; Xu, W.F. Viral RNA polymerase: a promising antiviral target for influenza A virus. Curr. Med. Chem. 2013, 20, 3923–3934.

[6] Dias, A.; Bouvier, D.; Crépin, T.; McCarthy, A.A.; Hart, D.J.; Baudin, F.; Cusack, S.; Ruigrok, R.W. The cap-snatching endonuclease of influenza virus polymerase resides in the PA subunit. Nature. 2009, 458, 914–918.

[7] Locke, S.C.; Splawn, L.M.; Cho, J.C. Baloxavir marboxil: a novel cap-dependent endonuclease (CEN) inhibitor for the treatment of acute uncomplicated influenza. Drugs Today. 2019, 55, 359–366.

[8] Noshi, T.; Kitano, M.; Taniguchi, K.; Yamamoto, A.; Omoto, S.; Baba, K.; Hashimoto, T.; Ishida, K.; Kushima, Y.; Hattori, K.; Kawai, M.; Yoshida, R.; Kobayashi, M.; Yoshinaga, T.; Sato, A.; Okamatsu, M.; Sakoda, Y.; Kida, H.; Shishido, T.; Naito, A. In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit. Antiviral Res. 2018, 160, 109–117.

[9] Heo, Y.A. Baloxavir: first global approval. Drugs. 2018, 78, 693–697.

[10] Watanabe, A.; Ishida, T.; Hirotsu, N.; Kawaguchi, K.; Ishibashi, T.; Shishido, T.; Sato, C.; Portsmouth, S.; Tsuchiya, K.; Uehara, T. Baloxavir marboxil in Japanese patients with seasonal influenza: Dose response and virus type/subtype outcomes from a randomized phase 2 study. Antiviral Res. 2019, 163, 75–81.

[11] Koshimichi, H.; Ishibashi, T.; Kawaguchi, N.; Sato, C.; Kawasaki, A.; Wajima, T. Safety, tolerability, and pharmacokinetics of the novel anti-influenza agent baloxavir marboxil in healthy adults: phase I study findings. Clin. Drug Investig. 2018, 38, 1189–1196.

[12] Kitano, M.; Matsuzaki, T.; Oka, R.; Baba, K.R.; Noda, T.; Yoshida, Y.; Sato, K.; Yoshida, R.; Sato, A.; Kamimori, H.; Shishido, T.; Naito, A.A. Therapeutic effects of baloxavir marboxil against influenza A virus infection in ferrets. Open Forum Infect. Dis. 2018, 5, S413.

[13] Cole, P. Baloxavir marboxil. Drugs Future. 2018, 43, 379–387.

[14] Hayden, F.G.; Sugaya, N.; Hirotsu, N.; Lee, N.; de Jong, M.D.; Hurt, A.C.; Ishida, T.; Sekino, H.; Yamada, K.; Portsmouth, S.; Kawaguchi, K.; Shishido, T.; Arai, M.; Tsuchiya, K.; Uehara, T.; Watanabe, A.; Baloxavir Marboxil Investigators Group. Baloxavir marboxil for uncomplicated influenza in adults and adolescents. N. Engl. J. Med. 2018, 379, 913–923.

[15] Nair, H.; Brooks, W.A.; Katz, M.; Roca, A.; Berkley, J.A.; Madhi, S.A.; Simmerman, J.M.; Gordon, A.; Sato, M.; Howie, S.; Krishnan, A.; Ope, M.; Lindblade, K.A.; Carosone-Link, P.; Lucero, M.; Ochieng, W.; Kamimoto, L.; Dueger, E.; Bhat, N.; Vong, S.; Theodoratou, E.; Chittaganpitch, M.; Chimah, O.; Balmaseda, A.; Buchy, P.; Harris, E.; Evans, V.; Katayose, M.; Gaur, B.; O’Callaghan-Gordo, C.; Goswami, D.; Arvelo, W.; Venter, M.; Briese, T.; Tokarz, R.; Widdowson, M.A.; Mounts, A.W.; Breiman, R.F.; Feikin, D.R.; Klugman, K.P.; Olsen, S.J.; Gessner, B.D.; Wright, P.F.; Rudan, I.; Broor, S.; Simões, E.A.; Campbell, H. Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis. Lancet. 2011, 378, 1917–1930.

[16] Kawaguchi, K.; Portsmouth, S.; Shishido, T.; Uehara, T.; Hayden, F. Exploring clinical and antiviral efficacy of baloxavir marboxil in a phase 3, randomized, double-blind, placebo- and active-controlled study of otherwise healthy adults/adolescents in seasonal influenza: impact on regional participants, treatment time and influenza type B virus infection (CAPSTONE-1 study). Open Forum Infect. Dis. 2018, 5, S48.

[17] Shionogi. Study of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir in Patients With Influenza at High Risk of Influenza Complications (CAPSTONE2). 2018, 07, 24. 2019, 02, 15. https//clinicaltrials.gov/ct2/show/NCT02949011term=Baloxavir+marboxil

[18] Ison, M.G. Phase 3 trial of baloxavir marboxil in high risk influenza patients (CAPSTONE-2 study). Open Forum Infect. Dis. 2018, 5, S764–S765.

[19] Japan Pharmaceuticals and Medical Devices Comprehensive Agency. Xofluza tablets. 2018, 02, 23. http://www. pmda.go.jp/PmdaSearch/iyaku Detail/Result Data Set PDF/340018_6250047F1022_1_01

[20] Drug Evaluation Department, Drug Safety and Environ-mental Health Bureau, Ministry of Health, Labour and Welfare, Japan. Ask Fruzac shackle review report. 2018, 02, 08. http://101.96.10.63/www.pmda.go.jp/drugs/2018/P20180312001/340018000_23000AMX00434000_ A100_1.pdf